This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

GE Healthcare To Showcase Innovative Breast Cancer Solutions From Screening Through Monitoring At SABCS 2012

GE Healthcare, the healthcare division of General Electric Company (NYSE:GE) is working to help physicians potentially improve patient care throughout the breast cancer journey through one of the most comprehensive portfolios of technologies in the industry available today. While at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS 2012), taking place in San Antonio from December 5-7, GE Healthcare will provide attendees with an overview of its innovative breast cancer solutions for healthcare practitioners. These innovations, which range from screening to diagnosis, then to staging, treatment planning and monitoring, recently received Frost & Sullivan's 2012 breast imaging product line strategy award for North America for having the most comprehensive portfolio and may have a transformational impact on breast cancer care delivery.

Visitors to the GE Healthcare booth (#225) at SABCS 2012 will also be able to speak with GE Healthcare experts and executives about its commitment to innovative patient-focused solutions. GE Healthcare is also sponsoring a presentation and panel discussion entitled “Enabling More Confident Decisions for Breast Cancer Treatment” on Thursday, December 6 at 2:00pm at the Product Theatre in the Exhibit Hall of the Henry B. Gonzalez Convention Center. Speakers and topics include:

  • Mammostrat – A Breast Cancer Recurrence Assay – Tamoxifen versus Exemestane Adjuvant Multicenter (TEAM) Trial Update - John M.S. Bartlett, MD, Director of Transformative Pathology at Ontario Institute of Cancer Research, Toronto, Ontario, Canada
  • Discordance in HER2 Testing in Metastatic Breast Cancer – VIRGO Trial Update - Edith Perez, MD, Deputy Director at Large, Mayo Clinic Cancer Center
  • New Updates and Advances in Ductal Carcinoma In Situ (DCIS) - Craig Allred, MD, Professor, Department of Pathology, Washington University School of Medicine

Additionally, results from three GE Healthcare-sponsored studies will be presented at SABCS 2012:

  • Presentation P2-10-04 -The Mammostrat Test is an Effective Tool to Stratify Patient Samples Previously Characterized as Intermediate by the Oncotype Dx Test – Thursday, December 6, 7:00 – 9:00am, Hall A-B
  • Presentation P3-05-05 - HER2 Expression and Gene copy analysis by Immunofluorescence and Fluorescence in situ Hybridization, on a Single formalin-fixed paraffin-embedded tissue section – Thursday, December 6, 5:00-7:00pm, Hall A-B
  • Presentation P3-05-06 - Automated Analysis of Her2 FISH Using Combined Immunofluorescence and FISH Signals – Thursday, December 6, 5:00-7:00pm, Hall A-B

“With a disease as complex and multi-faceted as breast cancer, innovations need to be equally multi-faceted and even more integrated in their scope, and GE Healthcare is fully committed to developing solutions that enable physicians to improve the quality of care provided to the patients they treat,” said Carrie Eglinton-Manner, CEO, Clarient Diagnostic Services, a GE Healthcare company. “The studies presented at SABCS in addition to the information being shared at the product theater are further demonstration of that commitment.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs